Clinical Study for Subjects With Coronavirus 2019 (COVID-19) Using Multiple Dose Intravenous Infusions of Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs)

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 13 Feb 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Adipose-derived autologous mesenchymal stem cell therapy-Celltex Therapeutics (Primary)
Indications COVID 2019 infections
Focus Adverse reactions; Therapeutic Use
Sponsors Celltex Therapeutics

05 Feb 2024 Planned initiation date changed from 1 Nov 2023 to 1 Nov 2024.
13 Apr 2023 Planned End Date changed from 15 Nov 2025 to 15 Nov 2026.
13 Apr 2023 Planned primary completion date changed from 1 Nov 2023 to 1 Nov 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com